The Latest Analyst Ratings For Adaptimmune Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have released mixed ratings for Adaptimmune Therapeutics (NASDAQ:ADAP) over the past three months, with a notable decrease in the average 12-month price target from $6.50 to $3.54. The company faces significant financial challenges, including a decline in revenue and below-average profitability metrics.
August 05, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adaptimmune Therapeutics has received mixed analyst ratings over the past three months, with a significant drop in the average 12-month price target from $6.50 to $3.54. The company is facing financial challenges, including a decline in revenue and below-average profitability metrics.
The mixed analyst ratings and significant drop in the average price target indicate a bearish sentiment. The company's financial challenges, including a substantial revenue decline and poor profitability metrics, further support a negative short-term outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100